106513-42-2

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL (S)-(-)-2-(TERT-BUTYLDIMETHYLSILYLOXY)PROPIONATE is used as a precursor for the synthesis of the lactyl-3,4-didehydroproline didemnin B side chain, which is an important component in the development of novel anticancer agents. Its unique structure allows for the efficient construction of complex molecular frameworks, making it a valuable tool in the design and synthesis of new pharmaceutical compounds.
Used in Chemical Industry:
ETHYL (S)-(-)-2-(TERT-BUTYLDIMETHYLSILYLOXY)PROPIONATE is used as a starting material for the asymmetric synthesis of synand anti-functionalized 1,2-diols. These diols are essential building blocks in the creation of various organic compounds, including those with potential applications in the fields of materials science, agrochemistry, and pharmaceuticals. The asymmetric synthesis facilitated by ETHYL (S)-(-)-2-(TERT-BUTYLDIMETHYLSILYLOXY)PROPIONATE allows for the selective production of specific isomers, which is crucial for the development of targeted and effective products.

InChI:InChI=1/C11H24O3Si/c1-8-13-10(12)9(2)14-15(6,7)11(3,4)5/h9H,8H2,1-7H3/t9-/m0/s1

Upstream product

• 687-47-8 (S)-Ethyl lactate 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 64-17-5 ethanol 
• 129919-88-6 (2S)-2-<(tert-Butyldimethylsilyl)oxy>lactic acid 

Downstream Products

• 155671-22-0 (S)-3-(tert-Butyl-dimethyl-silanyloxy)-1-((R)-toluene-4-sulfinyl)-butan-2-one 
• 74262-56-9 (2R)-2-(tert-butyldimethylsilyloxy)propanal 
• 243841-18-1 (2E,4S)-4-<(tert-butyldimethylsilyl)oxy>-2-penten-1-yl p-toluenesulfonate 
• 1069120-27-9 (S,Z)-4-((tert-butyldimethylsilyl)oxy)-N-((1s,4s)-4-((2E,4E)-5-((3R,5S)-7,7-dimethyl-1,6-dioxaspiro[2.5]octan-5-yl)-3-methylpenta-2,4-dien-1-yl)cyclohexyl)pent-2-enamide 

Relevant academic research and scientific papers

PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS

The invention provides new pyrazine derivatives of formula (I): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising sa

SHP2 INHIBITORS AND USES THEREOF

Compounds of Formula 1 as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases associated with the aberrant activity of SHP2 such as cancer using these compounds or compositions containing these compounds are also disclosed.

A Unified Strategy for the Asymmetric Synthesis of Highly Substituted 1,2-Amino Alcohols Leading to Highly Substituted Bisoxazoline Ligands

A general procedure for the asymmetric synthesis of highly substituted 1,2-amino alcohols in high yield and diastereoselectivity is described that uses organometallic additions of a wide range of nucleophiles to tert-butylsulfinimines as the key step. The addition of organolithium reagents to these imines follows a modified Davis model. The diastereoselectivity for this reaction depends significantly on both the nucleophile and electrophile. These highly substituted 1,2-amino alcohols are used to synthesize stereochemically diverse and structurally novel, polysubstituted 2,2′-methylene(bisoxazoline) ligands in high yields.

PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Disclosed in the present disclosure are a pyrimidine-fused cyclic compound or a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer, solvate or isotope labeled compound thereof. Also provided in the present disclosure are a preparation method for the compound, a composition comprising the compound and a use of the compound for the preparation of a medicament for the prevention and/or treatment of a disease or condition associated with abnormal SHP2 activity.

Synthesis of Methyl l -Kijanosides by Regio- And Stereoselective Ring Opening of 2-Oxazolidinone -Fused Aziridines

Kijanose is one of the most highly functionalized deoxysugars found in nature and a challenging synthetic target. We found that the ring opening of trisubstituted, 2-oxazolidinone-fused aziridines is regio- and stereoselective, and the azide adduct has the same stereochemistry as that of kijanose after converting the azido to a nitro group. Therefore, both α- and β-methyl l-kijanosides were prepared from ethyl l-lactate in 14% total yield.

HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2

A compound of formula (I):wherein Ring A, Q, R1,R2, R3, R4, R5, R6, R7, R8, R9, R10, R11,X, a,b, c and d are as defined in the specification.

IMIDAZOPYRIMIDINE DERIVATIVES

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating cancers.

METHODS AND COMPOSITIONS

The invention relates to genetic incorporation of 2,3-diamino propionic acid (DAP) into polypeptides, to unnatural amino acids comprising DAP, to a tRNA synthetase for charging tRNA with unnatural amino acids comprising DAP, and to methods of using the resulting polypeptides, for example in capturing substrates and/or intermediates in enzymatic reactions. The invention also relates to compounds of formula (I) or (II): or salts, solvates, tautomers, isomers or mixtures thereof.

Steric Enforcement of cis-Epoxide Formation in the Radical C-O-Coupling Reaction by Which (S)-2-Hydroxypropylphosphonate Epoxidase (HppE) Produces Fosfomycin

(S)-2-Hydroxypropylphosphonate [(S)-2-HPP, 1] epoxidase (HppE) reduces H2O2 at its nonheme-iron cofactor to install the oxirane "warhead" of the antibiotic fosfomycin. The net replacement of the C1 pro-R hydrogen of 1 by its C2 oxygen, with inversion of configuration at C1, yields the cis-epoxide of the drug [(1R,2S)-epoxypropylphosphonic acid (cis-Fos, 2)]. Here we show that HppE achieves ～95% selectivity for C1 inversion and cis-epoxide formation via steric guidance of a radical-coupling mechanism. Published structures of the HppE·FeII·1 and HppE·ZnII·2 complexes reveal distinct pockets for C3 of the substrate and product and identify four hydrophobic residues - Leu120, Leu144, Phe182, and Leu193 - close to C3 in one of the complexes. Replacement of Leu193 in the substrate C3 pocket with the bulkier Phe enhances stereoselectivity (cis:trans ～99:1), whereas the Leu120Phe substitution in the product C3 pocket diminishes it (～82:18). Retention of C1 configuration and trans-epoxide formation become predominant with the bulk-reducing Phe182Ala substitution in the substrate C3 pocket (～13:87), trifluorination of C3 (～23:77), or both (～1:99). The effect of C3 trifluorination is counteracted by the more constrained substrate C3 pockets in the Leu193Phe (～56:44) and Leu144Phe/Leu193Phe (～90:10) variants. The ability of HppE to epoxidize substrate analogues bearing halogens at C3, C1, or both is inconsistent with a published hypothesis of polar cyclization via a C1 carbocation. Rather, specific enzyme-substrate contacts drive inversion of the C1 radical - as proposed in a recent computational study - to direct formation of the more potently antibacterial cis-epoxide by radicaloid C-O coupling.

Synergistic substrate and catalyst effects in the addition of trimethylsilyl cyanide to imines derived from lactic acid

Trimethylsilylcyanide was added to various imines derived from (2S)-ethyl lactate in the presence of Lewis acids to provide both syn- and anti- β-hydroxy-α-aminonitrile stereoisomers. Syn-products were found to be the major in most instances, however, ant